(No ratings)
Dr. Jeffrey Mason Chambliss, MD is a physician provider in Dallas, TX specializing in physician, adult allergy & immunology, general pediatrics and pediatric allergy & immunology. He graduated from University of Texas Health Science Center at San Antonio, School of Medicine in 2013 and has 13 years of experience. Dr. Jeffrey Mason Chambliss, MD is affiliated with UT Southwestern Medical Center, Children's Health Specialty Center Dallas and Children's Health Specialty Center Dallas Campus.
Asthma
Asthma is a chronic lung disease where the tissue and airways of the lungs become extremely sensitive to certain substances. When these substances are breathed in, the lungs become inflamed. The muscles around the airways tighten and squeeze the lungs, and passages within the lungs swell and tighten. The airways themselves produce mucus, which further clogs the tightened, swollen airways. A person having an asthma attack finds it very difficult to breathe, and a severe attack can even be fatal.
Asthma affects people of all ages, but people with asthma are most often diagnosed as children. Symptoms can include wheezing, a tight feeling in the chest, shortness of breath, and coughing. Some people have mild symptoms all the time, and some people have no symptoms at all, but everyone with asthma is susceptible to occasional severe attacks or flare-ups of symptoms when they are exposed to triggers. Triggers vary widely but can include:
Treatment for most asthma patients involves three steps. Patients learn what their asthma triggers are and avoid them. They take a daily control medication, usually an inhaled corticosteroid, to reduce inflammation in the lungs. Also, they have rescue medication with them at all times to take in case of a severe attack. These quick-acting inhaled medications relax the muscles around the airways and allow the lungs to open up for air.
There is no cure for asthma, but with treatment it should not interfere with daily life and activities.
Dr. Jeffrey Mason Chambliss, MD graduated from University of Texas Health Science Center at San Antonio, School of Medicine in 2013. He completed residency at University of North Carolina Healthcare. He has a state license in Texas.
Medical School: University of Texas Health Science Center at San Antonio, School of Medicine (2013)
Residency: University of North Carolina Healthcare (2016)
Licensed In: Texas
Dr. Jeffrey Mason Chambliss, MD is associated with these hospitals and organizations:
Dr. Jeffrey Mason Chambliss, MD does not have any reviews yet, be the first to leave a review of Dr. Jeffrey Mason Chambliss, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Jeffrey Mason Chambliss, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Novartis Pharmaceuticals Corporation |
$1,569
XOLAIR $132 |
$1,438 |
||||
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP |
$365
TEZSPIRE $125 |
FASENRA $115 |
$125 |
|||
| Shire North American Group Inc |
$345
CUVITRU $201 |
Cinryze $144 |
||||
| Baxalta US Inc |
$226
HYQVIA $115 |
$111 |
||||
| Genentech USA, Inc. |
$186
XOLAIR $67 |
$119 |
||||
| Other |
$556
DUPIXENT $181 |
Haegarda $131 |
ATOPIC DERMATITIS - DISEASE $122 |
NUCALA $86 |
NIOX VERO DEVICE $20 |
Other $16 |
| Food and Beverage | $1,784 |
|---|---|
| Consulting Fee | $1,438 |
| Honoraria | $25 |
Dr. Jeffrey Chambliss' specialties are pediatric allergy & immunology, physician, and adult allergy & immunology. He has a special interest in asthma, angioedema, and atopic dermatitis. He is a graduate of the University of Texas Health Science Center at San Antonio, School of Medicine. Dr. Chambliss's medical residency was performed at a hospital affiliated with the University of North Carolina (UNC). His distinctions include: Texas Rising Stars; Texas Super Doctors Rising Star; and Texas Monthly. Dr. Chambliss speaks Spanish. He is professionally affiliated with UT Southwestern Medical Center. Dr. Chambliss's practice in Dallas, TX is open to new patients as reported by Yext.